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Abstract
Aims/hypothesis We investigated the risk associated with
HLA-B*39 alleles in the context of specific HLA-DR/DQ
haplotypes.
Methods We studied a readily available dataset from the
Type 1 Diabetes Genetics Consortium that consists of 2,300
affected sibling pair families genotyped for both HLA
alleles and 2,837 single nucleotide polymorphisms across
the major histocompatibility complex region.
Results The B*3906 allele significantly enhanced the risk of
type 1 diabetes when present on specific HLA-DR/DQ
haplotypes (DRB1*0801-DQB1*0402: p=1.6×10
−6,O R
25.4; DRB1*0101-DQB1*0501: p=4.9×10
−5, OR 10.3) but
did not enhance the risk of DRB1*0401-DQB1*0302 hap-
lotypes. In addition, the B*3901 allele enhanced risk on the
DRB1*1601-DQB1*0502 haplotype (p=3.7×10
−3,O R7 . 2 ) .
Conclusions/interpretation These associations indicate that
the B*39 alleles significantly increase risk when present on
specific HLA-DR/DQ haplotypes, and HLA-B typing in
concert with specific HLA-DR/DQ genotypes should
facilitate genetic prediction of type 1 diabetes, particularly
in a research setting.
Keywords Association study.Genetics.HLA class I.
HLA-B.HLA-B*39.MHC.Type 1 diabetes
Abbreviations
AFBAC Affected family based control
IMGT International ImMunoGeneTics information
system
SNP Single-nucleotide polymorphism
T1DGC Type 1 Diabetes Genetics Consortium
TDT Transmission disequilibrium test
WTCCC Wellcome Trust Case Consortium
Introduction
Alleles of multiple genes within the MHC region are
associated with type 1 diabetes. In particular, the HLA-
DRB1, HLA-DQA1 and HLA-DQB1 genes are most
strongly associated with type 1 diabetes. Specifically, the
common genotype with the highest risk for type 1 diabetes
in Europeans is DRB1*0301-DQA1*0501-DQB1*0201/
DRB1*04-DQA1*0301-DQB1*0302 (DR3/4), which is
present in 2.4% of the general US population [1, 2]. Class
I HLA alleles have also been associated with type 1
diabetes, particularly the HLA-B*39 and HLA-A*24 alleles
[3–6]. The high risk of HLA-B*3906 has been documented
for DRB1*0101-DQB1*0501 and DRB1*0801-DQB1*0402
chromosomes [4], and the B*3906 allele alone has been
associated with a younger age of onset of type 1 diabetes
[4, 5, 7, 8]. The risk of the B*3901 allele has not been well
documented.
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DOI 10.1007/s00125-011-2161-1B*3906 and B*3901 are the most common HLA-B*39
alleles. As we are interested in extended haplotypes that
span HLA-DR/DQ and HLA-B (both class I and class II
genes), in this paper we investigate associations of risk for
type 1 diabetes for multiple HLA-DR/DQ haplotype groups
with either the B*3906 or B*3901 allele. We show that
there is increased risk for both B*3906 and B*3901 on
specific HLA-DR/DQ haplotypes, and extend the analysis to
examine the single-nucleotide polymorphism (SNP)-level
variation of these haplotypes.
Methods
Study populations and genotyping
This analysis included 2,300 affected sibling-pair families
(10,012 individuals typed for HLA and/or SNPs) from the
Type 1 Diabetes Genetics Consortium (T1DGC), using the
2007.11.MHC data freeze [9]. Affected sibling pairs and
their parents were enrolled in nine cohorts worldwide.
Within the analysed cohorts of Asia-Pacific, Europe, North
America, UK, British Diabetes Association (BDA), Danish,
Human Biological Data Interchange (HBDI), Joslin and
Sardinian, 99% of individuals are classified as white or
unknown. The T1DGC performed basic quality control
analyses on the data. All study participants or their parents/
surrogates provided written informed consent to participate,
and the study protocol was approved by the relevant Ethics
Committees and Institutional Review Boards.
Genotyping was completed for 3,072 SNPs at the Well-
come Trust Sanger Institute, using custom Illumina exon-
centric and mapping panels (2957 distinct SNPs [1536 SNPs
in each panel with 115 overlapping SNPs] with 2837 of 2957
SNPs successfully typed, yielding a 96% SNP success rate).
In addition, complete four-digit HLA typing (HLA-DPB1,
HLA-DPA1, HLA-DQB1, HLA-DQA1, HLA-DRB1, HLA-B,
HLA-C and HLA-A), performed using immobilised probe
linear arrays, was available for all samples [10].
MICA genotyping To analyse association of HLA-B*39
with MICA alleles, we typed 341 T1DGC individuals who
had a B*39 allele or were family members of individuals
with a DRB1*0404 allele. MICA genotypes were deter-
mined using a fluorescence-based method as reported
previously by Zake et al., Park et al. and Triolo et al. [11–13].
Details of the exact method used by our laboratory have been
reported previously by Triolo et al. [13].
Data processing
SNP positions used NCBI Build 36 (National Center for
Biotechnology Information, U.S. National Library of
Medicine, Bethesda, MD, USA). T1DGC chromosomes
were generated from SNP and HLA genotype data using
multiple software packages. First, to establish that the
genotype data demonstrated a Mendelian inheritance
pattern within each family, the PedCheck program
(http://watson.hgen.pitt.edu)[ 14] was used on data from
both Illumina panels and HLA separately. Mendelian
inheritance patterns were present for all families. Next,
data from the Illumina mapping SNP panel, the exon-centric
SNP panel, and HLA were combined using custom Java
programs.Merlinsoftware(www.sph.umich.edu/csg/abecasis/
Merlin)[ 15] was used to phase the SNP and HLA genotype
data from families into chromosomes. In situations of
ambiguous phase (resulting from heterozygous SNPs or
HLA in all family members), phase was not inferred and
instead unphased alleles were labelled as such and were
excluded from analyses where appropriate.
Founder chromosomes were used in these analyses,
yielding four unique chromosomes per family. An affected
family based control (AFBAC) method was used to assign
case or control status to chromosomes using Microsoft
Excel macros as previously described [16–19]. Founder
chromosomes were labelled as case if they were ever
transmitted to a case individual. Correspondingly, chromo-
somes were labelled as control if they were never
transmitted to a case individual. Two affected children in
each family were used to label the chromosomes as either
case or control, as this was the ascertainment scheme for
T1DGC. Analysis of founder chromosomes avoids the
issues of non-independence of siblings in the family, as
only the four parental (founder) chromosomes are analysed
in every family.
Amino acid sequences for HLA-B*3906, B*3901 and
B*1402 were taken from the international ImMunoGeneTics
information system (IMGT) database (www.ebi.ac.uk/imgt/
hla/align.html). Three-dimensional modelling of the HLA-B
peptide binding region was performed using IMGT
(http://imgt.cines.fr/3Dstructure-DB/)[ 20].
Statistical analysis
The Fisher’s exact test (two-sided) was used to calculate
p values for AFBAC founder chromosome association with
type 1A diabetes, with α=0.05.
Each founder chromosome was classified as transmitted
or not transmitted based on transmission to one randomly
selected case child in each family. A modified transmission
disequilibrium test (TDT) was used to evaluate the
significance for each HLA-DR/DQ group by comparing,
within each HLA-DR/DQ group, the number of B*3906
alleles transmitted to an affected individual, the number of
B*3906 alleles not transmitted to an affected individual, the
number of non-B*3906 alleles transmitted to an affected
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transmitted to an affected individual. These values were
compared using the Fisher’s exact test (α=0.05). The same
logic was used for B*3901. The underlying counts were
computed using custom Java programs, which are available
upon request.
Relative risk for the DRB1*08-B*39/DRB1*03 genotype
was analysed using case T1DGC individuals (one case per
family) and calculated control-genotype frequencies taken
from non-transmitted control T1DGC chromosomes. We
required the B*39 allele to be present on the DRB1*08
chromosome, not the DRB1*03 chromosome. Relative
risk was calculated using Graph Pad 4.0, and the absolute
risk estimate was based on a background population risk
of 1/300.
For Fig. 1 and electronic supplementary material (ESM)
Figs 1–3, consensus sequences were identified using an
automated version of the process previously described for
evaluating extended haplotypes [21]. Briefly, given a
haplotype matrix consisting of a range of contiguous SNPs
and a specific number of chromosomes, we identified the
most common sequence of SNPs over a small window or
subrange of, for example, 30 SNPs. Then, we narrowed the
window to a smaller number of SNPs (e.g. ten) and repeated
the process, thereby deriving a consensus sequence for the
entire range. Additionally, as the sequence emerged, we
scored each chromosome for identity with the emerging
sequence. Chromosomes that did not sufficiently match the
consensus were eliminated from further consideration. A
consensus sequence was derived for the B*3906 chromo-
somes in the region surrounding the HLA-B gene, and then
the other groups of chromosomes were compared with this
B*3906 consensus in Fig. 1 and ESM Figs 1–3.
The number of chromosomes differs between Fig. 1
and the ESM figures because of the logic that excludes a
chromosome from congruence analysis if more than 20%
of the SNPs within the range of consideration are
unknown or unphased. As Fig. 1 and the ESM figures
consider different ranges, different chromosomes fail
across those ranges.
 Fig. 1 Comparison of HLA-B alleles based on SNPs. Each column is
a chromosome and each row is a SNP. a HLA-B*3906 chromosomes
compared with HLA-B*3906 consensus (124 chromosomes, 219 SNPs
and 0.26 Mb). b HLA-B*3901 chromosomes compared with HLA-
B*3906 consensus (80 chromosomes, 219 SNPs and 0.26 Mb). c
HLA-B*1402 chromosomes compared with HLA-B*3906 consensus
(144 chromosomes, 219 SNPs and 0.26 Mb). The same consensus
sequence was used in a–c, and was based on B*3906 chromosomes.
The chromosomes are organised by HLA-DR/DQ type in each figure
part, and only the region surrounding the HLA-B gene is shown.
Yellow boxes show that the allele matches that of the B*3906
consensus, whereas blue represents the opposite allele. The telomeric
end of the MHC is at the top of the graph. Type 1 diabetes case
chromosomes are on the left and control chromosomes are on the right
1704 Diabetologia (2011) 54:1702–1709Results
We interrogated a readily available dataset from the T1DGC to
examine the risk associated with the two most common HLA-
B*39 alleles, B*3906 and B*3901.T h eB*3906 allele is
present in 2.6% of case and 0.4% of control chromosomes,
while B*3901 is present in 1.3% of case and 1.0% of control
chromosomes. Using case and control chromosomes classified
using an AFBAC method, the B*3906 allele is associated
with very high risk for type 1 diabetes (127/141 B*3906 [90%
case chromosomes] vs 4963/7650 non-B*3906 [65% case],
p=1.1×10
−11, OR 4.9). These results combine all HLA-DR/
DQ haplotypes together and look at the overall risk of each
allele only. Overall, the B*3901 allele was not significantly
associated with type 1 diabetes (68/95 B*3901 [72% case] vs
5022/7696 non-B*3901 [65% case] p=0.2, OR 1.3). We
next investigated the associations of specific HLA-DR/DQ
haplotypes with B*3901 and B*3906 (Table 1). The great
majority of B*3901 and B*3906 alleles are concentrated on
relatively few HLA-DR/DQ haplotypes. Specifically, B*3906
is present almost exclusively on DRB1*0101-DQB1*0501,
DRB1*0801-DQB1*0402,a n dDRB1*0401-DQB1*0302
haplotypes, whereas B*3901 is present on DRB1*0101-
DQB1*0501 and DRB1*1601-DQB1*0502 haplotypes.
We then assessed the risk of both B*39 alleles on these
stratified HLA-DR/DQ haplotypes compared with the results
presented earlier which are not stratified by HLA-DR/DQ
haplotype. B*3906 is associated with case chromosomes on
DRB1*0801-DQB1*0402 (p=1.6×10
−6,O R2 5 . 4 ,T a b l e2)
and is also associated on DRB1*0101-DQB1*0501 haplo-
types (p=4.9×10
−5, OR 10.3). There is a trend toward
increased association of the HLA-B*3906 allele on other
HLA-DR/DQ haplotypes, with the exception of DRB1*0401-
DQB1*0302 where there is no increased risk associated with
the B*3906 allele (p=0.7, OR 0.8). When we examine the
B*3901 allele, we find that it is associated with case
chromosomes on the DRB1*1601-DQB1*0502 haplotype
(p=3.7×10
−3, OR 7.2, Table 3). B*3901 was not signifi-
cantly associated with diabetes on other HLA-DR/DQ
haplotypes. Analysis of transmission of these B*39-bearing
haplotypes to one affected child per family is concordant
with the above case/control analyses (Tables 4 and 5). Both
B*3906 and B*3901 significantly enhance type 1 diabetes
risk, each on specific HLA-DR/DQ haplotypes.
The B*3906 and B*3901 amino acid sequences are
closely related, and their nearest non-B*39 HLA-B allele is
B*1402 [22]. We decided to investigate these three alleles
in more detail. Only two amino acids differ between the
B*3906 and B*3901 alleles, both in the base of the peptide-
binding pocket (B*3906 to B*3901: threonine to arginine
and tryptophan to leucine). When we compare B*1402 and
B*3906, they differ by seven amino acids, five of which
appear to be in the peptide-binding region. However, despite
this apparent similarity at the amino acid sequence level, the
B*1402 allele does not enhance diabetes risk (82/163
B*1402 [50% case] vs 5008/7628 non-B*1402 [66% case],
p=8.2E−5, OR 0.5). B*1402 is marginally associated with
decreased type 1 diabetes risk on DRB1*0701-DQB1*0201
and DRB1*0301-DQB1*0201 haplotypes (ESM Table 1).
We analysed SNPs surrounding the HLA-B gene for the
three HLA-B alleles of interest to determine the SNP-level
differences (Fig. 1a–c). In these figures, each column is one
chromosome (panels showing B*3906, B*3901 or B*1402
chromosomes, respectively) and each row is one SNP. These
figures only show the region surrounding the HLA-B gene
(full chromosome plots can be found in ESM Figs 1–3). All
three groups of chromosomes are compared with a common
consensus sequence for B*3906. Yellow boxes represent
SNP alleles that match the consensus while blue represents
SNP alleles that do not match the consensus. All three
groups of chromosomes (B*3906, B*3901 and B*1402)a r e
congruent (or match) for a region of SNPs surrounding HLA-
B (59,530 base pairs), even though B*3906 and B*3901 are
associated with higher risk and B*1402 is not. B*3901 and
B*3906 chromosomes are congruent (based on SNPs) with
each other for 142,861 base pairs surrounding HLA-B.W e
typed a subset of families for the MICA gene, which is in the
region of SNP identity, enriching for families with B*39.O f
the individuals (a mixture of patients and unaffected
individuals from T1DGC families) with the B*39 allele,
100% had the MICA 9 allele (26/26) vs 17% of individuals
without B*39 (54/314, p=1.3×10
−18).
Discussion
HLA-B*39 risk has been well defined in the literature [3, 4,
7, 8]. With the characterisation of conserved extended
Table 1 Distribution of B*3901 and B*3906 alleles on HLA-DR/DQ
haplotypes
Haplotype Total B*3906 B*3901
DRB1 DQB1 n %o fD R n %o fD R
*0101 *0501 477 29 6.08 11 2.31
*0801 *0402 153 37 24.18 4 2.61
*0401 *0302 1,153 19 1.65 8 0.69
*0301 *0201 1,674 10 0.60 8 0.48
*1601 *0502 131 5 3.82 17 12.98
Other – 2,323 26 1.12 32 1.38
HLA-DR/DQ groups are shown in the table if there were at least ten
chromosomes with either B*3906 or B*3901. B*3906 and B*3901 are
present on relatively few HLA-DR/DQ haplotypes.
The ‘other’ group consists of all HLA-DR/DQ haplotypes that are not
specified in the table
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exploring the genetic context of HLA-B*39 alleles (via
haplotype and SNP analysis) have become increasingly
important in further characterising haplotypic risk for type 1
diabetes and those MHC regions involved in risk determi-
nation [4, 24, 25]. Here we confirm previously discovered
haplotypic associations of HLA-B*39 alleles, and place
these associations in the context of high-density SNP
analysis.
B*3906 is associated with increased risk on
DRB1*0801-DQB1*0402 and DRB1*0101-DQB1*0501
haplotypes, whereas B*3901 is associated with increased
risk on DRB1*1601-DQB1*0502 haplotypes. While both
B*39 alleles are associated with increased risk, B*1402,
their nearest non-B*39 HLA-B allele by amino acid
sequence, is not associated with increased risk [22]. Even
one amino acid difference, particularly in the peptide-
binding region, could influence disease risk associated with
the allele. Therefore, even though there are only seven
amino acid differences (five in the peptide-binding region)
between B*1402 and B*3906, those changes could result in
the drastic difference in risk seen in this analysis. In
addition, as there are two amino acid differences between
B*3906 and B*3901, both in the peptide-binding region,
those differences could also result in differences in disease
risk. Therefore, we hypothesise that B*39-associated
increased risk is due to the differences in amino acid
sequence between B*3901/B*3906 and B*1402 or that the
risk is associated with polymorphisms where B*3906 and
B*3901 are congruent for almost all SNPs but do not
match the B*1402 SNP haplotype. Gene-conversion
events between alleles of the HLA-B gene have been
reported previously. This is one possible explanation for
the presence of highly similar SNP sequences surrounding
the HLA-B gene for the B*3906, B*3901 and B*1402
alleles [26–28].
There are five genes in the 142,861 base pair region of
near SNP identity between the B*3906 and B*3901
haplotypes: HLA-B, DHFRP2 (dihydrofolate reductase
pseudogene 2), HLA-S (pseudogene), MICA (MHC class I
polypeptide-related sequence A), and HLA-X (pseudogene).
Theoretically, any of these genes or even variations in non-
coding sequence in the region could contribute to the
increased risk associated with B*3901 and B*3906.
Table 2 The HLA-B*3906 allele is significantly associated with type 1 diabetes on specific HLA-DR/DQ haplotypes
Haplotype Case Control OR (95% CI) p value
DRB1 DQB1 With B*3906 Without B*3906 % with
B*3906
With
B*3906
Without
B*3906
% with
B*3906
*801 *402 36 68 35 1 48 2.0 25.4 (3.37–191.8) 1.6×10
−6
*101 *501 27 254 10 2 194 1.0 10.31 (2.42–43.89) 4.9×10
−5
*401 *302 17 1034 1.6 2 100 2.0 0.82 (0.19–3.61) 0.68
*301 *201 10 1365 0.7 0 299 0.0 4.61 (0.27–78.82) 0.22
Other – 26 1458 1.8 5 1423 0.4 5.19 (1.94–13.25) 1.9×10
−4
Analysis of T1DGC AFBAC case and control chromosomes for the risk associated with B*3906, stratified by HLA-DR/DQ haplotype
B*3906 is associated with case chromosomes on DRB1*0801-DQB1*0402 (p=1.6×10
−6, OR 25.4) and DRB1*0101-DQB1*0501 haplotypes
(p=4.9×10
−5, OR 10.3)
The ‘other’ group consists of all HLA-DR/DQ haplotypes that are not specified in the table
Table 3 The HLA-B*3901 allele is significantly associated with type 1 diabetes on specific HLA-DR/DQ haplotypes
Haplotype Case Control OR (95% CI) p value
DRB1 DQB1 With B*3901 Without B*3901 % with B*3901 With B*3901 Without
B*3901
% with
B*3901
*1601 *502 15 58 21 2 56 3.4 7.24 (1.58–33.12) 3.68×10
−3
*101 *501 8 273 2.8 3 193 1.5 1.89(0.49–7.2) 0.54
Other – 34 3774 0.9 18 1785 1.0 0.89(0.5–1.59) 0.77
Analysis of T1DGC AFBAC case and control chromosomes for the risk associated with B*3901, stratified by HLA-DR/DQ haplotype
B*3901 is associated with case chromosomes on the DRB1*1601-DQB1*0502 haplotype (p=3.7×10
−3, OR 7.2)
The ‘other’ group consists of all HLA-DR/DQ haplotypes that are not specified in the table
1706 Diabetologia (2011) 54:1702–1709There are limitations to this work. First, B*39 is not a
common allele, as we see it in only 3% of individuals with
type 1 diabetes in this dataset. Consequently, we cannot tell
whether B*3906 haplotypes confer greater risk than B*3901
haplotypes as the only HLA-DR/DQ haplotype that is
common to both alleles is DRB1*0101-DQB1*0501,a n dt h e
numbers in this group are too small to distinguish the risk
associated with the alleles. Therefore, a larger dataset is
needed to fully differentiate the risk associated with these two
B*39 alleles. It has been previously described that the B*3906
allele is high risk on the DRB1*0404-DQB1*0302 haplotype
[8, 29, 30]. Our results are in the same direction, but a larger
dataset would be needed to confirm the effect (DRB1*0404-
DQB1*0302:9 / 9B*3906 [100% of B*3906 are case
chromosomes] compared with 249/304 non-B*3906 [82% of
non-B*3906 a r ec a s ec h r o m o s o m e s ] ,p=0.4, OR 4.2).
We did not observe a difference in risk due to the
B*3906 allele on the DRB1*0401-DQB1*0302 haplotype
(DRB1*0401-DQB1*0302: 17/19 B*3906 [89% of B*3906
are case chromosomes] compared with 1034/1134 non-
B*3906 [91% of non-B*3906 are case chromosomes],
p=0.7, OR 0.82). It is possible that the DRB1*0401-
DQB1*0302 risk is so high that we are unable to see an
incremental effect from B*3906. In addition, as the
numbers in the B*3906-DRB1*0401-DQB1*0302 group
are small, it is possible that the study was underpowered to
find an association. Similarly, the B*3901 allele is rare
(1.2%). The current study should be considered hypothesis-
generating given the limited number of chromosomes
containing B*39, even in this large T1DGC dataset.
To replicate our findings from the T1DGC dataset we
employed a large, publicly available dataset from the Well-
come Trust Case Consortium (WTCCC) [5] (ESM Table 2).
Diplotypes containing high-risk DRB1-DQB1 haplotypes
(namely DRB1*0801-DQB1*0402, DRB1*0101-
DQB1*0501, DRB1*301-DQB1*0302, DRB1*0401-
DQB1*0302,a n dDRB1*1601-DQB1*0502) were evaluated
for the presence of HLA-B*3906 and HLA-B*3901.T h o s e
containing DRB1*0801-DQB1*0402 (but not the other high-
risk haplotypes) were more likely to have HLA-B*3906 (case
42% [8/19], control 6% [3/53], p=6.3×10
−4, OR 12).
Similar results were found for genotypes containing
DRB1*0101-DQB1*0501 (case 9% [7/81], control 2%
[7/367], p=5.8×10
−3,O R5 )a n dDRB1*0301-DQB1*0201
(case 5% [25/502], control 1% [9/628], p=6.7×10
−4,O R4 ) .
Our finding that the haplotype DRB1*0401-DQB1*0302 is
not associated with HLA-B*3906 was also confirmed, with
similar frequency between cases (3% [5/181]) and controls
(2% [3/186], p=0.5).
Our analyses using both the T1DGC and WTCCC
datasets, therefore, indicate that HLA-B*3906 is high risk
on specific DRB1-DQB1 haplotypes. At a practical level,
identifying specific HLA-DR/DQ haplotypes also carrying
B*39 will aid type 1 diabetes genetic prediction for
individuals, particularly in a research setting. In terms of
quantificative risk and application in a clinical setting,
Table 4 Transmission of the B*3906 allele
Haplotype B*3906 Not B*3906 p value
DRB1 DQB1 Transmitted to affected Not transmitted to affected Transmitted to affected Not transmitted to affected
*0101 *0501 23 6 190 255 1.5×10
−4
*0301 *0201 10 0 1,111 546 0.04
*0401 *0302 14 3 877 253 0.8
*0404 *0302 8 1 197 105 0.2
*0801 *0402 29 8 50 65 2.7×10
−4
Other (≤5) – 16 6 582 1,201 0.2
TDT analysis was completed to calculate the transmission of B*3906 to one case individual per family, stratified by HLA-DR/DQ alleles
HLA-DR/DQ groups with five or fewer B*3906 alleles are combined into an ‘other’ category
Table 5 Transmission of the B*3901 allele
Haplotype B*3901 Not B*3901 p value
DRB1 DQB1 Transmitted
to affected
Not
transmitted
to affected
Not
transmitted
to affected
Not
transmitted
to affected
*0101 *0501 6 4 207 257 0.4
*0301 *0201 6 2 1,115 544 1
*0401 *0302 6 2 885 254 1
*0404 *0302 6 0 199 106 0.1
*1601 *0502 12 5 42 72 0.02
Other (≤5) – 10 20 511 1,133 0.8
TDT analysis was completed to calculate the transmission of B*3901
to one case individual per family, stratified by HLA-DR/DQ alleles
HLA-DR/DQ groups with five or fewer B*3901 alleles are combined
into an ‘other’ category
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critical determinates, especially such high-risk diplotypes as
DR3/4 with HLA-B*3906. In that the B*39 alleles are
uncommon among patients with type 1 diabetes, identifying
B*39 alleles will have little impact on the prediction of
overall risk of type 1 diabetes (as illustrated by an ROC
curve). In particular, absence of a B*39 allele would not
appreciably decrease the overall risk of type 1 diabetes. In
contrast the very high odds ratios of B*39 in combination
with specific HLA-DR/DQ alleles (e.g. DRB1*0801-
DQB1*0402) indicate that for individuals carrying these
genotypes there would be a potentially important increase
in risk with the presence of B*39. Absolute diabetes risk of
genotype DRB1*08-B*39/DRB1*03 is estimated to be 5%,
compared with 0.26% when B*39 is not present with this
same genotype. This 5% risk for the DRB1*08-B*39/
DRB1*03 genotype is comparable with the risk seen with
the highest risk genotype DR3/4.
From a theoretical point of view, if the effects of B*39
alleles are dependent on both specific HLA-DR/DQ
haplotypes and in particular the specific B*39 sequences,
it suggests a potentially complex model of pathogenesis.
The leading hypothesis is that B*39 alleles present specific
islet peptides to CD8 T lymphocytes. HLA-DR/DQ alleles
might determine CD4 T cells targeting of specific auto-
antigens and B*39 alleles would then enhance CD8 T cells
targeting of peptides of these autoantigens. Alternatively it
is possible that class I polymorphisms may even influence
thymic selection and the repertoire of CD4 T cell receptors.
Understanding the mechanism by which B*39 alleles
enhance diabetes risk on specific HLA-DR/DQ haplotypes
will likely contribute to our overall understanding of the
loss of tolerance leading to type 1 diabetes.
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